Overactive Bladder Treatment Market 2027 Top Companies, Trends and Growth Factors Details by Regions Report
Overactive bladder (OAB) is a functioning problem of bladder and not a disease. OAB is a combination of different symptoms such as frequent urination, urine leakage, urgency to urinate, as well as the need to urinate at least twice every night. There are various causes which can result to OAB such as Urinary Tract Infection (UTI), weak pelvic muscles, obesity, nerve damage due to trauma or diseases, hormonal imbalance post menopause, caffeine, medications, and alcohol. Moreover, multiple sclerosis, Parkinson’s disease, and stroke are few of the diseases that can lead to an overactive bladder. Surgery, Botox bladder treatment, medications, certain behavioral changes such as diet change and bladder retraining are generally adopted as therapeutics for OAB. Darifenacin, Oxybutynin, Trospium, Solifenacin, and Fesoterodine are anticholinergic medications that are commonly prescribed for OAB. These anticholinergic medications block the receptors present on the walls of urinary bladder to decrease the muscle activity and thus, provide relief from urine urgency problem and frequency of urination. However, the side effects associated with these medications are dry mouth, constipation, and blurred vision. Additionally, Beta-3 adrenergic drug such as Mirabegron (Myrbetriq) are also prescribed to relax bladder muscles and increase the bladder capacity to hold the urine for a longer period of time.
Global Overactive Bladder Therapeutics Market: Dynamics
Rising geriatric population and increasing awareness about the treatments available for overactive bladder syndrome are the major drivers for overactive bladder therapeutics market. For instance, according to a report published by the U.S. Department of Health & Human Services 2018, approximately 25 million individuals suffered from urinary incontinence in the U.S.
Moreover, key market players are adopting various strategies such as collaborations, product launches, product approvals, partnerships and patents, which is expected to drive the market growth in the near future. For instance, in May 2018, Astellas Pharma Inc., a Japan-based multinational pharmaceutical company, received the U.S. Food and Drug Administration (U.S. FDA) approval for use of mirabegron in combination with solifenacin succinate to treat the symptoms associated with OAB. Moreover, in February 2020, Allergan, an AbbVie company, launched Botox for the treatment of overactive bladder syndrome in those patients who did not respond well or were intolerant to commonly used anticholinergic and beta-3 adrenergic drugs. Botox is the first U.S. FDA approved neurotoxin, which is indicated for the treatment of overactive bladder syndrome in children.
In addition, the U.S. FDA is also aiming at increasing the number of approvals for generic drugs and decreasing the cost of the drugs to encourage more companies to launch their products in the market. For instance, in December 2020, Urovant Sciences received the U.S. FDA approval for GEMTESA (Vibegron), which is indicated to treat symptoms such as leakage, urinary urgency, and high frequency of urination in adults who are suffering from OAB.
Global Overactive Bladder Therapeutics Market: Restraints
Side effects associated with the treatment of OAB is the major factor restraining the growth of the market. For instance, in 2020, according to an article published by the National Center for Biotechnology Information (NCBI), anticholinergic drug- Oxybutynin used in the treatment of overactive bladder syndrome may cause dry mouth, constipation, and dizziness. Additionally, Beta-3 adrenergic drug such as Mirabegron (Myrbetriq) show common adverse drug events such as dry mouth, Urinary tract Infection (UTI), hypertension, diarrhea, headache, and constipation. Botox treatment can also pose a high risk of Urinary Tract Infections. All these factors can hamper the growth of the overactive bladder therapeutics market during the forecast period. Furthermore, patent expiry of key drugs such as Oxybutynin which are commonly prescribed for the treatment of OAB can also hinder the market growth. For instance, Oxybutynin patent issued to Watson Pharmaceuticals, Inc. in 2016 would expire in 2029.
Global Overactive Bladder Therapeutics Market: Regional Insights
North America is expected to hold the largest market share during the forecast period in overactive bladder therapeutics market owing to the rise in the prevalence of overactive bladder syndrome, increasing geriatric population, and medical advancements. For instance, according to Global Forum on Incontinence (GFI) in 2018, around 9% of North American population had urinary incontinence. Additionally, in 2020, the National Association for Incontinence reported that around 25 million adults suffer from urinary incontinence (leakage) in the U.S.
Europe is the second largest market in the global overactive bladder therapeutics market due to increase in research and development activities, supportive government initiatives, and rise in the occurrences of overactive bladder syndrome. For instance, the U.K.’s National Institute for Health and Care Excellence (NICE) provides the benefit of reimbursement every year for patients adopting Botox Therapy for the treatment of overactive bladder syndrome.
The Asia Pacific market is projected to grow during the forecast period owing to rising awareness about the overactive bladder syndrome and aggressive marketing strategies of the manufacturers. Moreover, an increase in the approvals of drugs used in the treatment of OAB by regulatory bodies such as the U.S Food and Drug Administration drives the growth of the market in the Asia Pacific region. For instance, in April 2020, Granules Pharmaceuticals, Inc., owned by Granules India Ltd., got the U.S. FDA approval for use of Trospium Chloride capsules for the treatment of urine urgency and urine incontinence in patients suffering from overactive bladder syndrome.
Global Overactive Bladder Therapeutics Market: Key Trends
In March 2021, KYORIN Pharmaceutical and Eisai Co. Ltd., Japan-based firms, signed a license agreement for the development and marketing of Vibegron drug indicated for the treatment of overactive bladder syndrome in Thailand, Malaysia, Brunei, and the Philippines.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2007
Overactive Bladder Treatment Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.
Main points in Overactive Bladder Treatment Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Overactive Bladder Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Overactive Bladder Treatment Industry Impact
Chapter 2 Global Overactive Bladder Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Overactive Bladder Treatment (Volume and Value) by Type
2.3 Global Overactive Bladder Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Overactive Bladder Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Overactive Bladder Treatment Market Analysis
Chapter 6 East Asia Overactive Bladder Treatment Market Analysis
Chapter 7 Europe Overactive Bladder Treatment Market Analysis
Chapter 8 South Asia Overactive Bladder Treatment Market Analysis
Chapter 9 Southeast Asia Overactive Bladder Treatment Market Analysis
Chapter 10 Middle East Overactive Bladder Treatment Market Analysis
Chapter 11 Africa Overactive Bladder Treatment Market Analysis
Chapter 12 Oceania Overactive Bladder Treatment Market Analysis
Chapter 13 South America Overactive Bladder Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Overactive Bladder Treatment Business
Chapter 15 Global Overactive Bladder Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
- CDN Newswire